Oil-Based Microparticle Suspension for Intestinal Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions fail to effectively enhance the bioavailability of hardly water-soluble active ingredients, particularly for oral administration, as they often result in high excretion in feces and lack efficient absorption from the intestinal tract.
Innovation Solution
A pharmaceutical composition comprising a suspension of microparticles of a medicinally-active ingredient in a base oil, with a mean particle diameter of 20 µm or smaller, specifically designed for oral administration, where the microparticles are suspended in a base oil with additives like suspending and dispersing agents, enhancing absorption and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Length of moving object
If microparticles of several hundreds nanometers are prepared by dry grinding, then particle size is reduced, but handling becomes difficult and coagulation occurs in aqueous medium
Solution Approach 1:
The patent introduces an oily suspension as an intermediary medium to prevent direct contact between microparticles and aqueous environment. The oil-based suspension acts as a protective barrier, allowing microparticles to be administered without coagulation while maintaining small particle size for improved bioavailability.
Solution Approach 2:
The patent changes the physical state of the drug delivery system from dry powder to oily suspension. This parameter change transforms the system from one where particles directly contact aqueous media (causing coagulation) to one where particles are stabilized in an oily medium, fundamentally altering the interaction properties.
2Reliability
If particle diameter is reduced to enhance absorption, then bioavailability improves, but manufacturing complexity increases
Solution Approach 1:
The patent performs particle size reduction and suspension formulation in advance during manufacturing. By preparing the oily suspension of microparticles beforehand, the system ensures optimal particle size for absorption while simplifying the actual administration process, as no further size reduction is needed at the point of use.
Solution Approach 2:
The patent creates a composite system combining microparticles with an oily suspension medium. This composite approach integrates particle size control, suspension stability, and bioavailability enhancement into a single formulated product, reducing the need for separate manufacturing steps for each function.
3Ease of operation
If aqueous suspension is used for hardly water-soluble compounds, then administration is simplified, but absorption and bioavailability remain poor
Solution Approach 1:
The patent inverts the conventional approach by using an oily suspension instead of an aqueous suspension for hardly water-soluble compounds. This inversion recognizes that oil-based media are more compatible with lipophilic drugs, improving dissolution and absorption while maintaining ease of administration through soft capsule formulation.
4Reliability
If fine microparticles are prepared, then intestinal absorption is enhanced, but excretion in feces increases without proper suspension
Solution Approach 1:
The oily suspension acts as an intermediary that facilitates intestinal absorption while preventing premature excretion. The oil medium allows microparticles to maintain stability during transit through the gastrointestinal tract, enabling sufficient time for absorption while preventing the particles from being excreted intact in feces.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition significantly reduces the rate of excretion in feces and increases bioavailability, achieving extremely high intestinal absorption and retention of the active ingredient, particularly for p38MAP kinase inhibitors used in treating inflammatory bowel diseases.
Implementation Method 1
a pharmaceutical composition comprising a suspension of microparticles of a medicinally-active ingredient in a base oil
Implementation Method 2
they are hardly wetted with water, and they coagulate in an aqueous medium
Data Source
Figure 1
AI summary
A pharmaceutical composition comprising a suspension of medicinally-active ingredient microparticles having a mean particle diameter of 20 µm or smaller in a base oil which can achieve extremely high intestinal absorption and bioavailability especially when the medicinally-active ingredient is hardly water-soluble.